Name: Paul Jones
Nationality: British (United Kingdom)
Highest Academic Degree: MBA
Institution / University: Sheffield University Management School, UK
Professional Career
Paul Jones has more than three decades of experience in life sciences, spanning pharma, consulting, big tech, and digital health. As the Chief Strategy Officer & GM, International Markets at Halia Therapeutics he is responsible for corporate and commercial leadership outside the US, based from Abu Dhabi. He leads on strategic fundraising and partnership development as well as technology and innovation integration.
Prior to this role Paul was CEO of BioPharma Solutions at M42 where he forged partnerships with industry at the interface to the Emirati Genome Programme – weaving genomic research into national health priorities to deliver precision medicines with a population-level impact.
Paul has been directly involved in genomics-related activity for the last decade. Notably, he was the founding CEO of Genomics Enterprises, the arm of Genomics England responsible for all commercial aspects of the 100,000 Genomes Project. This was a pioneering initiative that, to this day, continues to significantly advance our understanding of rare diseases and cancer. Moreover, it resulted in the formation of the NHS Genomic Medicine Service, the first national health care system to offer whole genome sequencing as part of routine care.
Paul’s experience as the former Head of Population Genomics at Illumina, Inc. – where he orchestrated large-scale genomic programmes across more than 50 countries – gave him further understanding of how to translate genomic insights into real-world impact on a global scale. These combined experiences underscore his commitment to building bridges between governments, academia, industry, and health systems, fostering innovation whilst driving economic growth.
Paul’s career also includes serving as Chairman of Sonrai Analytics, a company with an AI-enabled analytics platform supporting diagnostic and personalised therapy development. He was CEO of Vortex Biosciences, where he led the development of a liquid biopsy technology supporting the development of personalised medicines, guiding therapy selection and monitoring cancer. Additionally, his earlier career highlights include leading global life sciences at Cisco, leading global eMarketing and eSales at Novartis, and a role as Management Consultant at PwC, specialising in life sciences.
Research Interest
Paul is researching the different approaches available to biopharma firms, when engaging with innovation ecosystems around large-scale genomic datasets.
Research Specialty
Innovation in biopharma at the interface to healthcare systems around the world.
Statement of Motivation for a DBA
With over three decades of global life sciences leadership experience, my mission has been to commercialise and scale precision medicines and emerging health technologies to achieve population-level impact. The convergence of genomics, data science and the recent emergence of AI is creating a fundamental shift for the biopharma industry. Massive population datasets are being created that present unprecedented opportunity but also complex strategic challenges for leaders in the biopharma industry.
The central problem is the lack of a coherent strategic framework for biopharma firms and investors to effectively create, capture, and defend value within the complex and varied innovation ecosystems forming around large-scale genomic data assets. This challenge is multifaceted: firms must navigate the upstream complexities of AI-driven drug discovery, master a radically new downstream commercialisation landscape, and critically, align their strategies with the agendas of multiple powerful ecosystem orchestrators, all while navigating the inherent tension between the high cost of targeted therapies and the societal need for affordable population health.
I want to use my DBA to provide a robust theoretical underpinning to help biopharma industry leaders make better practical strategic choices that not only benefit their organisations but ensure long-term societal benefit.
